Subacute cutaneous lupus erythematosus in a patient of pancreatic cancer secondary to novel albumin-bound paclitaxel chemotherapy

Abstract

Paclitaxel is commonly used for the treatment of breast, ovarian, gastrointestinal, and carcinoma of the head and neck. Paclitaxel treatment is often associated with hair loss, myalgia, acral erythema, scleroderma and Stevens–Johnson syndrome, peripheral neuropathy, nausea, vomiting, bone marrow suppression, and rarely cardiac electroconductive pathway abnormalities. However, its association with cutaneous/systemic lupus erythematosus has been sparsely described. In this case report, we are discussing a case of nab-paclitaxel-induced subacute cutaneous lupus erythematosus which has been described only once in the published literature.